Clinical reference Biomarker Directory
Back to directory

Anti-cyclic Citrullinated Peptide

Established

Anti-CCP is the most specific serologic marker for rheumatoid arthritis, useful for diagnosis, not monitoring.

Also known as Anti-CCP ACPA anti-citrullinated protein antibody
In plain language

Anti-CCP is the most specific blood test for rheumatoid arthritis and can show up years before joint symptoms start. It's excellent for diagnosis but shouldn't be used to check whether treatment is working.

Biomarker & context

Anti-cyclic citrullinated peptide (anti-CCP or ACPA) antibodies target citrullinated proteins and are the most specific blood marker currently available for rheumatoid arthritis (RA).

What it indicates

Anti-CCP positivity strongly supports an RA diagnosis and can appear years before clinical symptoms begin — studies using stored military sera found a median lead time of 4.5 years before RA onset, a finding of interest for early-intervention research.

Diagnosis & clinical testing

Measured via immunoassay; the 2010 ACR/EULAR RA classification criteria weight high-titer anti-CCP (or rheumatoid factor) equally, contributing up to 3 of the 10 points needed for classification alongside joint involvement, acute phase reactants, and symptom duration.

Guiding treatment

Evidence shows anti-CCP is useful for diagnosis but not for tracking disease activity or treatment response — it should not be used as a biomarker for monitoring how well RA therapy is working.

Clinical significance

Can predate clinical RA onset by years; combined with RF in current classification criteria.

References
  1. 2010 ACR/EULAR Classification Criteria for Rheumatoid Arthritis.
  2. Nielen, M. M., et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis. Arthritis & Rheumatism.